Statement: Only 6 patients in cohort 1 of the primary trial had Varicose Veins.
Primary_evidence: Adverse Events 1:   Total: 1/6 (16.67%)   Goitre 0/6 (0.00%)   Haemorrhoid Operation 0/6 (0.00%)   Sciatica 0/6 (0.00%)   Renal Failure 0/6 (0.00%)   Varicose Vein 1/6 (16.67%) Adverse Events 2:   Total: 2/7 (28.57%)   Goitre 1/7 (14.29%)   Haemorrhoid Operation 1/7 (14.29%)   Sciatica 1/7 (14.29%)   Renal Failure 1/7 (14.29%)   Varicose Vein 0/7 (0.00%)